CMET-18. IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES

BACKGROUND: Immunotherapy is increasingly used in patients with non-small cell lung cancer brain metastases (NSCLCBM). KRAS mutations are associated with worse prognosis and there is no FDA approved targeted therapy. KRAS mutations are associated with increased expression of PD-L1. We evaluated the...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Lauko, Adam, Ali, Assad, Sagar, Soumya, Barnett, Addison, Li, Hong, Chao, Samuel, Stevens, Glen, Pennell, Nathan, Peereboom, David, Yu, Jennifer, Murphy, Erin, Angelov, Lilyana, Funchain, Pauline, Mohammadi, Alireza, Suh, John, Barnett, Gene, Ahluwalia, Manmeet
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2019
Gaiak:
CNS Metastasis
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847893/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.219
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak